KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Other financing activities (2020 - 2025)

Esperion Therapeutics' Other financing activities history spans 6 years, with the latest figure at $244000.0 for Q4 2025.

  • For Q4 2025, Other financing activities fell 97.47% year-over-year to $244000.0; the TTM value through Dec 2025 reached $8.5 million, down 13.05%, while the annual FY2025 figure was $244000.0, 97.47% down from the prior year.
  • Other financing activities reached $244000.0 in Q4 2025 per ESPR's latest filing, down from $400000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $9.6 million in Q4 2024 to a low of -$438000.0 in Q4 2022.
  • Average Other financing activities over 5 years is $1.5 million, with a median of $400000.0 recorded in 2023.
  • Peak YoY movement for Other financing activities: skyrocketed 45738.1% in 2024, then crashed 97.47% in 2025.
  • A 5-year view of Other financing activities shows it stood at $500000.0 in 2021, then tumbled by 187.6% to -$438000.0 in 2022, then skyrocketed by 104.79% to $21000.0 in 2023, then surged by 45738.1% to $9.6 million in 2024, then crashed by 97.47% to $244000.0 in 2025.
  • Per Business Quant, the three most recent readings for ESPR's Other financing activities are $244000.0 (Q4 2025), $400000.0 (Q3 2025), and $400000.0 (Q2 2025).